18 May 2021
Braveheart Investment Group plc
("Braveheart" or the "Group")
Appointment of Non-Executive Director
Braveheart Investment Group (AIM: BRH) is pleased to announce the appointment of Dr Susan (Sue) Anne Hagan as a Non-Executive Director to the Board, with effect from today. She will also be a member of the Remuneration, Audit and Compliance committees.
Dr Sue Hagan brings a wide range of experience in research, development and commercialization of medical devices, in-vitro diagnostic (IVD) medical devices, therapeutics and related healthcare products. Currently, Sue is working on a COVID-19 in-vitro diagnostic point of care device, assisting with regulatory and clinical issues. Previously, with start-up biotech Astrimmune Ltd, she was instrumental in obtaining grants leading to collaborations with the University of Sheffield and the University of Cambridge for the development of a non-invasive bladder cancer monitoring test.
Sue works with start-up biotechs, NHS spin-offs, SMEs and Big Pharma and has managed clinical studies for oncology diagnostics and medical software, alongside regulatory affairs and grant applications. This effort included one of the earliest registrations of software as medical device in the EU based on an innovative retrospective trial design. Previously, she led early phase combination drug-device projects with Pfizer and was project manager for the development of a radiopharmaceutical oncology product into a first in human trial at Aphton Biopharma, a NASDAQ listed immunotherapeutic company, where she led the Research and Development Laboratory.
Sue is a registered pharmacist with a BSc from the University of Manchester and PhD from the University of Nottingham. She is the founder and CEO of Ourami Ltd, a creative solutions provider.
Trevor Brown, CEO of Braveheart commented, "We are very pleased that Sue has agreed to join the Board of Braveheart. I am confident that Sue's experience in the development of medical devices and management of clinical studies will be an important asset to the Company."
For further information:
|
|
|
| Braveheart Investment Group plc | Tel: 01738 587555 |
| Trevor Brown CEO |
|
|
|
|
| Allenby Capital Limited (Nominated Adviser and Joint Broker) | Tel: 020 3328 5656 |
| David Worlidge / James Reeve / George Payne |
|
|
|
|
| Peterhouse Capital Limited (Joint Broker) | Tel: 020 7469 0936 |
| Heena Karani / Lucy Williams |
|
Additional Information
Susan Anne Hagan (formerly Haigh), aged 51 years, is a director of Astrimmune Limited and Ourami Limited.
No further information is required to be disclosed under AIM Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
